| Condition | Oral manifestation or complication | Dental management |
| Childhood cancers | Decreased immune function, leading to gingival inflammation and alveolar bone loss | Reduction of plaque and microorganisms through oral hygiene and use of chemotherapeutic agents, such as chlorhexidine |
| Chemotherapeutic immunosuppression | Oral ulceration; infection by opportunistic organisms | Reduction of plaque and microorganisms through oral hygiene and use of chemotherapeutic agents, such as chlorhexidine |
| Graft-versus-host disease | Mucositis, xerostomia, oral pain | Artificial saliva, chemotherapeutic agents to reduce plaque, pain control measures |
| HIV infection | Severe acute and chronic gingival and periodontal inflammation, exceeding that expected for local irritants present | Reduction of plaque and microorganisms through oral hygiene and use of chemotherapeutic agents, such as chlorhexidine |
| Diabetes mellitus | Increased gingival and periodontal inflammation and increased risk of odontogenic infections | Reduction of plaque and microorganisms through oral hygiene and use of chemotherapeutic agents, such as chlorhoxidine |
| Congenital heart disease | Cyanotic friable oral tissues; ingress of microorganisms implicated in infective endocarditis | Adherence to American Heart Association guidelines for prevention of infective endocarditis[1] |
| Sickle cell anemia | Nonspecific oral findings, but at increased risk for infection secondary to dental treatment in some cases | Prophylaxis with appropriate antibiotic when needed for dental treatment |
